StockData
Metagenomi Therapeutics, Inc. logo

Metagenomi Therapeutics, Inc. (MGX) company profile

MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.63+0.00 (+0.13%)

Close on Nov 18, 2026Market cap $23.87MP/E –Yield –

About Metagenomi Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Metagenomi Therapeutics, Inc. is a genetic medicines company that develops next-generation genome editing systems to create curative therapies for patients. The company focuses on research and development efforts in genome editing using programmable nucleases, base editing, and RNA- and DNA-mediated integration systems, which include prime editors and CRISPR-associated transposases. It has not yet commercialized any product candidates and conducts research and development activities through strategic collaborations and license agreements with pharmaceutical partners such as Ionis and Moderna.

The company operates in a single operating segment focused on the development of its genome editing platform and therapies. It conducts preclinical studies and development programs in the United States and has established collaborations with third-party partners. Metagenomi Therapeutics, Inc. maintains its principal executive offices and laboratory facilities in Emeryville, California.

Summary of the business section of Metagenomi Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Metagenomi Therapeutics, Inc.
Headquarters
Emeryville, CA
Address
5959 Horton Street, 7th Floor 94608
Phone
(510) 871-4880
Employees
119, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, San Jose, California

Stock & identifiers

Ticker
MGX
Exchange
Nasdaq
IPO date
Feb 12, 2024
Shares outstanding
38M, Aug 6, 2026
Public float
$50.93M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1785279
CUSIP
59102M104
ISIN
US59102M1045
FIGI
BBG00Y5ZXS77
Share class FIGI
BBG00Y5ZXS95
EIN
81-3909017

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jian IrishSee Remarks, Director668,107
Matthew WeinSee Remarks126,133
Pamela WapnickChief Financial Officer206,580
Sarah B. NoonbergChief Medical Officer109,135
Laurence ReidDirector20,000
Eric BjerkholtDirector–
Willard H. DereDirector51,275
Juergen EckhardtDirector–
Brian C. ThomasDirector2,510,960

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Brian C. Thomas
Former Chief Executive Officer
$563.01K$42.24K$191.06K–$599.75K$1.40M-77%
Jian Irish
President and Chief Executive Officer
$570.66K$427.96K$402.78K$252.59K$13.93K$1.67M-56%
Pamela Wapnick
Chief Financial Officer
$464.00K$210.48K$81.88K$161.10K$17.50K$934.96K-74%
Matthew L. Wein
General Counsel, Compliance Officer, Head of BD&L and Corporate Secretary
$407.15K$163.40K$43.48K$124.86K$17.50K$756.38K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 12, 2024
Offer price
$15.00
Securities offered
6,250,000
Gross proceeds
$93.75M
Exchange
Nasdaq
First trading day
Feb 9, 2024
First-day close
$10.31-31.3%
Lock-up ends (est.)
Aug 7, 2024

“The initial public offering price of our common stock is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 119 full-time employees, of which 39 have M.D.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jan 12, 2026Name changeName changed from Metagenomi, Inc. to Metagenomi Therapeutics, Inc.
Feb 12, 2024IPOInitial public offering priced (424B4 prospectus)
Feb 5, 2024ListingRegistration of securities on an exchange (Form 8-A)
Jan 18, 2024Name changeName changed from Metagenomi Technologies, LLC to Metagenomi, Inc.

See a number that looks wrong?